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Multinodular goiter (MNG) is a common disorder characterized by a nodular enlargement of the thyroid gland
and occurring with a female:male ratio of 5:1. This article reports the analysis of an Italian three-generation
pedigree MNG, including 10 affected females and 2 affected males. After linkage to candidate regions previously
implicated in various forms of goiter was excluded, a novel MNG locus was searched. Because no male-to-male
transmission was present in the study pedigree, an X-linked autosomal dominant pattern of inheritance was hy-
pothesized. Therefore, 18 markers spaced at 10-cM intervals on the X chromosome were examined. A significant
LOD score was observed in the Xp22 region, where marker DXS1226 generated a maximum LOD score of 4.73
at a recombination fraction of 0. Analysis of six flanking microsatellites confirmed these data, and haplotype
inspection delimited a 9.6-cM interval lying between DXS1052 and DXS8039.
Nontoxic thyroid goiter is a common disorder char-
acterized by a diffuse or nodular enlargement of the
thyroid gland (multinodular goiter [MNG] [MIM
138800]), an enlargement that is not the result of an
inflammatory or neoplastic process. It is generally agreed
that the disease represents a compensatory response to
the impairment of thyroid hormonogenesis: as a con-
sequence of the increases in thyroid mass and unit func-
tional activity, a normal rate of hormonal secretion is
restored, so that the patient is eumetabolic but goitrous
(Ingbar and Woeber, 1968). The incidence of MNG is
dependent on sex (female:male ratio 5:1) and on the
iodine intake of the population (World Health Organ-
ization 1993, p. 1). Although MNG incidence may be
110% in endemic areas, the persistence of MNG in
regions with sufficient iodine intake has been docu-
mented in several reports, which supports the notion of
a genetic basis for the disease (Greig et al. 1967). More-
over, several authors have reported goiter families with
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vertical and/or male-to-male transmission, suggesting an
autosomal dominant susceptibility (Murray et al. 1966;
Bignell et al. 1997; Neumann et al. 1999). Actually, the
genetic analysis of one Canadian pedigree, showing no
skewed female:male ratio, has allowed the assignment
of the MNG1 locus to chromosome 14q (Bignell et al.
1997). This location has subsequently been confirmed
in a German pedigree with similar features (Neumann
et al. 1999). In addition, the molecular characterization
of many forms of goiter has revealed the presence of
mutations in several genes involved in thyroid hormon-
ogenesis. In particular, mutations have been detected in
thyroid peroxidase, thyroglobulin, sodium iodide sym-
porter member 5, thyrotropin receptor, and pendrin
genes (Ieiri et al. 1991; Abramowicz et al. 1992; Corral
et al. 1993; van Sande et al. 1995; Everett et al. 1997;
Fujiwara et al. 1997).
We report the linkage analysis of a three-generation
sex-biased Italian pedigree with MNG, leading to the
assignment of a novel MNG locus on chromosome
Xp22. The examined pedigree included 22 individuals
(fig. 1), whose clinical classification was based on both
palpation and ultrasonographic examination. Thyroid
ultrasound examination was performed using real-
time instruments (model AU5 Harmonic; ESAOTE) and
a 7.5-MHz linear transducer. Thyroid volume was cal-
culated according to the formula of the ellipsoid model
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Figure 1 Pedigree of family with multinodular goiter (MNG). Blackened bars denote at-risk haplotypes.
(width# length# thickness# .52) for each lobe. The
propositus (subject II:1 in fig. 1) was a 41-year-old
woman living in the mildly endemic goiter area of Mon-
talbano Jonico (Matera, Italy). She carried an MNG
(three nodules) and was euthyroid at diagnosis. No thy-
roid autoantibodies were detected. The parents of the
propositus were nonconsanguineous; the mother and all
five sisters were affected by either MNG or diffuse goiter
(only one individual), whereas both brothers were un-
affected. In the third generation, five of nine subjects
were affected. One of them (III:4) displayed low posi-
tivity for antithyroperoxidase antibodies. A total of 12
affected subjects (10 females and 2 males) were identi-
fied. The mean age at onset was 20.6 years (range 6–40
years). Thyroid volume was 22–66 ml in adult patients.
In adolescent patients, the thyroid volume was 14–16
ml. Thyroid hormone levels were within the normal
range in all members of the family. In addition, all family
members had normal somatic and intellectual develop-
ment and showed no signs of hypothyroidism.
Genomic DNA was obtained from peripheral blood
lymphocytes, by use of standard phenol-chloroform ex-
traction methods. In a first phase, we tested linkage at
the MNG1 locus and at several regions containing genes
implicated in the biosynthesis of thyroid hormone. The
latter candidate loci included the deiodinase I gene on
chromosome 1p32 (Mandel et al. 1992), the thyroperox-
idase gene on 2p24 (Abramowicz et al. 1992), the pen-
drin gene on 7q31 (Everett et al. 1997), the thyroglob-
ulin gene on 8q24 (Ieiri et al. 1991), the genes for
thyrotropin receptor (van Sande et al. 1995) and deiod-
inase III (Salvatore et al. 1995) on 14q31, the deiodinase
II gene (Croteau et al. 1996) on 14q24, the thyroid tran-
scription factor 1 gene on 14q13 (Ikeda et al. 1995),
and the sodium iodide symporter gene on chromosome
19p13 (Fujiwara et al. 1997). Pairs of microsatellite
markers flanking each candidate locus were selected
for genotyping, on the basis of the map locations re-
ported at the GeneCard Web site. Markers D14S62 and
D14S68 were used to test linkage at the MNG1 locus.
Two-point LOD scores were calculated using the
MLINK program from the LINKAGE (version 5.2)
package (Lathrop and Laouel 1984). The model used
assumed an autosomal dominant trait (frequency .02)
segregating with .95 penetrance. This analysis generated
LOD scores !3.00 at recombination fraction (v) 0, for
all loci examined (data not shown but available, on re-
quest, from the corresponding author).
At this stage, we undertook the search for a novel
MNG locus. Because the pedigree showed an excess of
affected females and presented no instance of male-to-
male transmission, we hypothesized an X-linked auto-
somal dominant pattern of inheritance. Therefore, we
did not analyze any additional autosomal region but,
instead, typed 18 markers spaced at ∼10-cM intervals
on the X chromosome, with the use of primers from the
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Table 1
Two-Point LOD Scores between the MNG Disease
Locus and Seven Markers Mapping to Chromosome
Xp22
MARKER
LOD SCORE AT v p
.00 .05 .1 .2 .3
DXS987  1.74 .65 .17 .34
DXS7105  1.24 1.54 1.50 1.11
DXS1052  1.80 2.05 1.90 1.40
DXS1226 4.73 4.36 3.97 3.10 2.13
DXS989 4.73 4.36 3.97 3.10 2.13
DXS8039  1.54 .45 .07 .14
DXS1214  3.88 2.47 1.17 .52
Figure 2 Multipoint LOD-score analysis of four markers span-
ning the MNG locus on chromosome Xp22. Arrows indicate the po-
sition of DXS1226 and DXS989.
ABI-Prism linkage mapping set (P-E Biosystems). We
used the MLINK and LINKMAP programs to compute
two-point and multipoint LOD scores, under the as-
sumption of X-linked autosomal dominant inheritance
with .95 penetrance. A frequency of 1/n was used for
each marker allele, where n is the number of alleles at
the examined locus. Although this assumption is unlikely
to hold true in the examined population, a misspecifi-
cation of allele frequencies is not expected to cause errors
in the linkage analysis of the pedigree, in which geno-
types are available for all the affected and disease-trans-
mitting individuals. Indeed, we simulated a set of various
marker-allele frequencies and always obtained the same
two-point LOD scores. Because of the constraints im-
posed by the amount of computer memory available,
only genotypes of loci DXS1052, DXS1226, DXS989
and DXS8039 were used for multipoint analysis.
A significant two-point LOD score was observed in
the Xp22 region, where marker DXS1226 generated a
maximum LOD score (Zmax) of 4.73 at v p 0 (table 1).
The analysis of six flanking microsatellites confirmed
these data (table 1). Haplotype inspection disclosed key
recombination events between DXS1052 and DXS1226,
in individuals III:3 and III:4, thereby defining the telo-
meric boundary of the disease interval (fig. 1). The cen-
tromeric limit is determined by a crossover, between
DXS989 and DXS8039, that was observed in subjects
II:4 and III:1 (fig. 1). Therefore, the MNG locus lies
within the 9.6-cM region delimited by the DXS1052 and
DX8039 markers. As expected, the multipoint LOD-
score curve peaks within this interval (fig. 2), further
confirming the disease-locus position.
Genes in the disease region include those encoding
dystrophin (DMD), sperimidin acetyl transferase (SAT),
pyruvate dehydrogenase kinase-3 (PDK3), DNA poly-
merase a (POLA), and zinc-finger protein X-linked
(ZFX). However, none seems an obvious candidate gene
for the MNG phenotype. On the other hand, the disease
region also harbors several mapped expressed sequence
tags (ESTs), whose characterization may identify more-
attractive candidate genes.
Our data indicate that the MNG phenotype observed
in this pedigree is not due to the impairment of any gene
known to be directly involved in thyroid hormono-
genesis. This finding is consistent both with the fact that
this biochemical pathway has not been fully elucidated
and with the general agreement that additional proteins
are likely to be involved. In this context, the genetic
characterization of extended pedigrees with goiter can
become a powerful tool for the identification of such
proteins. This approach has already proved successful,
since its application to pedigrees with Pendred syn-
drome has led to the isolation of the pendrin gene (PDS),
which encodes a transmembrane protein that transports
iodide and chloride (Everett et al. 1997; Scott et al.
1999). Therefore, we are endeavoring to recruit addi-
tional extended pedigrees with X-linked MNG, which
may allow us to refine the disease-locus position. Al-
though MNG has proved to be a genetically heteroge-
neous disease, the exclusion of families showing male-
to-male transmission and no sex bias among the affected
group is expected to eliminate most non–X-linked ped-
igrees from our sample. In this context, the isolation of
theMNG gene, mapping to the Xp22 locus, may become
feasible by a combination of positional cloning (further
refinement of disease locus) and positional-candidate
strategies (characterization of Xp22 ESTs).
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